{[(4-Fluorophenyl)sulfonyl]amino}acetic acid, 97.0%, 1g

Ethyl 4-Methyl-2-(thiophen-2-yl)thiazole-5-carboxylate, 95.0%, 100mg

5,7-Dibromo-1H-indazole, 95.0%, 1g

2-Methyl-5-formylpyridine, 95.0%, 5g

Anilina, mínimo 99 %, para síntesis, 2,5 l, envase de vidrio

Benzothiazol-4-ylamine, 95.0%, 25g

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)benzaldehyde, 98%, 1g

BENZYL ((5-METHYLPIPERIDIN-2-YL)METHYL)CARBAMATE HCL, 95.0%, 100mg

Oxion Inverso OX.2003-PLPH con objetivos LWD Plan fase 10x/20x/40x

2,6-Dichloropyridine-4-carboxylic acid, 97.0%, 50g

3-Hydroxy-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-2-naphthamide, 95.0%, 1g

Cefotiam hexetil hydrochloride, 95.72%, 25mg

4-Methoxybenzonitrile, 99.00%, 5g